Hepatitis C virus E1/E2 heterodimers and methods of producing same
AssigneeThe Governors of the University of Alberta
InventorsMichael Houghton, Darren Hockman, John L. Law, Chao Chen, Michael Logan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.
Claims11
An affinity tagged heterodimeric polypeptide comprising:
- a) a hepatitis C virus (HCV) E1 polypeptide having a length of from about 175 amino acids to about 195 amino acids;
- and
- b) an affinity-tagged HCV E2 polypeptide comprising, in order from N-terminus to C-terminus:
- i) an Ig Fc polypeptide;
- ii) a proteolytically cleavable linker, wherein the proteolytically cleavable linker comprises an amino acid sequence selected from the group consisting of LEVLFQGP as set forth in SEQ ID NO:1, ENLYFQS as set forth in SEQ ID NO:2, DDDDK as set forth in SEQ ID NO:3, I(E/D)GR as set forth in SEQ ID NO:45, and LVPRGS as set forth in SEQ ID NO:5;
- and
- iii) an HCV E2 polypeptide having a length of from about 350 amino acids to about 370 amino acids.
Dependencies are inferred from the claim text.